Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial | Dementia and Cognitive Impairment | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.234.102. Please contact the publisher to request reinstatement.
1.
Akiyama H, Barger S, Barnum S.  et al.  Inflammation and Alzheimer's disease.  Neurobiol Aging.2000;21:383-421.Google Scholar
2.
McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies.  Neurology.1996;47:425-432.Google Scholar
3.
Rogers J, Kirby LC, Hempelman SR.  et al.  Clinical trial of indomethacin in Alzheimer's disease.  Neurology.1993;43:1609-1611.Google Scholar
4.
Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.  Neurology.1999;53:197-201.Google Scholar
5.
Aisen PS, Davis KL, Berg JD.  et al.  A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study.  Neurology.2000;54:588-593.Google Scholar
6.
Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study.  Lancet.2001;358:455-460.Google Scholar
7.
in t' Veld BA, Ruitenberg A, Hofman A.  et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.  N Engl J Med.2001;345:1515-1521.Google Scholar
8.
Lim GP, Yang F, Chu T.  et al.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.  J Neurosci.2000;20:5709-5714.Google Scholar
9.
Lim GP, Yang F, Chu T.  et al.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice.  Neurobiol Aging.2001;22:983-991.Google Scholar
10.
Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.  Neuroscience.1998;87:319-324.Google Scholar
11.
Bazan NG, Lukiw WJ. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1 beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells.  J Biol Chem.2002;277:30359-30367.Google Scholar
12.
Andreasson KI, Savonenko A, Vidensky S.  et al.  Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.  J Neurosci.2001;21:8198-8209.Google Scholar
13.
Xiang Z, Ho L, Valdellon J.  et al.  Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology.  Neurobiol Aging.2002;23:327-334.Google Scholar
14.
Ho L, Purohit D, Haroutunian V.  et al.  Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.  Arch Neurol.2001;58:487-492.Google Scholar
15.
McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease.  Neurobiol Aging.2001;22:799-809.Google Scholar
16.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group.  Neurology.1984;34:939-944.Google Scholar
17.
Folstein M, Folstein S, Mchugh P. The Mini-Mental State Examination.  J Psychiatr Res.1975;12:189-198.Google Scholar
18.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease.  Am J Psychiatry.1984;141:1356-1364.Google Scholar
19.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.  Neurology.1993;43:2412-2414.Google Scholar
20.
Galasko D, Bennett D, Sano M.  et al.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease.  Alzheimer Dis Assoc Disord.1997;11(suppl 2):S33-S39.Google Scholar
21.
Cummings J. The neuropsychiatric inventory: assessing psychopathology in dementia patients.  Neurology.1997;48 (suppl 6):S10-S16.Google Scholar
22.
Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: patient and caregiver reports.  J Mental Health Aging.1999;5:21-32.Google Scholar
23.
Zeger S, Liang K-Y. Longitudinal data analysis fordiscrete and continuous data.  Biometrics.1986;42:121-130.Google Scholar
24.
Weggen S, Eriksen JL, Das P.  et al.  A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.  Nature.2001;414:212-216.Google Scholar
25.
Steinbach G, Lynch PM, Phillips RK.  et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med.2000;342:1946-1952.Google Scholar
26.
Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use.  Neurology.1997;48:626-632.Google Scholar
27.
in't Veld BA, Ruitenberg A, Hofman A.  et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.  N Engl J Med.2001;345:1515-1521.Google Scholar
28.
Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.  Neurology.1995;45:51-55.Google Scholar
29.
 Prevention of Alzheimer's and cognitive decline: grant 7U01AG015477-03. Available at: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen. Accessed February 2003.
Original Contribution
June 4, 2003

Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Department of Neurology, Georgetown University Medical Center, Washington, DC (Dr Aisen); Department of Neurosciences, University of California, San Diego (Ms Schafer and Drs Grundman, Jin, and Thal); Suncoast Gerontology Center, University of South Florida College of Medicine, Tampa (Dr Pfeiffer); Department of Psychiatry (Dr Sano), Mount Sinai School of Medicine, Mount Sinai Medical Center (Dr Davis), New York, NY; Department of Neurology, School of Medicine, Indiana University, Indianapolis (Dr Farlow); Departments of Family and Preventive Medicine and Neurosciences, University of California, San Diego (Dr Thomas).

JAMA. 2003;289(21):2819-2826. doi:10.1001/jama.289.21.2819
Abstract

Context Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease.

Objective To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD.

Design Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications.

Setting Forty ambulatory treatment centers affiliated with the Alzheimer's Disease Cooperative Study consortium.

Participants Participants with mild-to-moderate AD (Mini-Mental State Examination score of 13-26) were recruited from December 1999 to November 2000 using clinic populations, referrals from community physicians, and local advertising. Stable use of cholinesterase inhibitors, estrogen, low-dose aspirin, and vitamin E was allowed. Participants with inflammatory diseases that might respond to the study medications were excluded. Of 474 participants screened, 351 were enrolled.

Interventions Once-daily rofecoxib, 25 mg, or twice-daily naproxen sodium, 220 mg, or placebo.

Main Outcome Measures The primary outcome measure was the 1-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score. Secondary outcome measures included the Clinical Dementia Rating scale sum-of-boxes, the Neuropsychiatric Inventory, the Quality of Life-AD, and the time to attainment of significant end points (4-point decline from baseline ADAS-Cog score, 1-step worsening on the global Clinical Dementia Rating scale, 15-point decline on the ADCS activities of daily living inventory, institutionalization, or death).

Results The 1-year mean (SD) change in ADAS-Cog scores in participants treated with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not significantly different from the change in participants treated with placebo (5.7 [8.2]). Results of secondary analyses showed no consistent benefit of either treatment. Fatigue, dizziness, and hypertension were more commonly reported in the active drug groups, and more serious adverse events were found in the active treatment group than in the placebo group.

Conclusion The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.

×